Viva Biotech Holdings
No.735, Ziping Road
Zhoupu Town Pudong New District
Shanghai 201318
China
86 21 6089 3288
https://www.vivabiotech.com.cn
版塊: Healthcare
行業: Biotechnology
全職員工: 2,077
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Chen Cheney Mao Ph.D. | Chairman & CEO | 216.35k | 無 | 1962 |
| Mr. Ying Wu M.B.A. | Executive VP & Executive Director | 176.04k | 無 | 1963 |
| Dr. Delin Ren Ph.D. | Executive Director | 305.73k | 無 | 1961 |
| Mr. Zheren Wang C.F.A. | Co-Chief Financial Officer | 無 | 無 | 1984 |
| Mr. Wei Xiong | Co-Chief Financial Officer | 無 | 無 | 1984 |
| Mr. Xueheng Cheng Ph.D. | Chief Technology Officer | 無 | 無 | 1956 |
| Dr. Zhixiong Ye Ph.D. | Chief Scientific Officer | 無 | 無 | 1960 |
| Mr. Han Dai Ph.D. | Chief Innovation Officer & Head of Viva BioInnovator | 無 | 無 | 1980 |
| Mr. Jianhua Cai Ph.D. | Senior Vice President | 無 | 無 | 無 |
| Jianguo Ma Ph.D. | Senior VP & CEO of Langhua Pharmaceutical | 無 | 無 | 無 |
描述
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody/biologics research and development services comprising recombinant protein expression platform, antibody discovery and affinity maturation, assay platform, antibody production and identification platform, and antigen-antibody structural resolution platform solutions. It also offers PROTAC/molecular glue services, including protein preparation and ternary complex structure determination, screening for molecule glues and novel E3 ligase ligands, PROTAC ternary complex kinetics, PROTAC degradation assays and ternary complex assays, PROTAC molecule design and synthesis, ADME & PK/PD studies of PROTAC molecules, and computer aided PROTAC design solutions; and XDC platforms, such as XDC conjugation and quality study, XDC chemistry research and development, and XDC functional studies. In addition, the company offers contract development and manufacturing services comprising integrated services for small molecule active pharmaceutical ingredients, formulation development and production services, and pharmaceutical analysis services, as well as CMC filing, global filing registration support, and other services. Further, it provides laboratory rental, and project management and bidding services, as well as sells compounds. The company was incorporated in 2008 and is headquartered in Shanghai, China.
公司管治
截至 無 止，Viva Biotech Holdings 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
